Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prescription medication costs are forcing some hard choices for many Nevadans. Two years ago, a proposal that offered hope sailed through the Democrat-majority Nevada Legislature only to be vetoed ...

Its diabetes treatments Januvia and Janumet are now facing stiff price competition, while its HPV vaccine Gardasil is running into headwinds in China.

Merck added that its drugs Janumet and Janumet XR were selected for the second round of negotiations, with those prices slated to take effect in January 2027. "The company expects that in 2026 ...

The negotiated prices for the Janumet franchise will take effect in 2027. Merck was the first of many drugmakers to sue the U.S. government in 2023 over the “sham” pricing negotiations ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

Although collective sales for Januvia and Janumet fell 33% last year (when including the adverse impact of changing currency-exchange rates), these diabetes treatments combined still account for ...

and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

Prevymis recorded sales of $215 million, up 23% year over year. Januvia/Janumet (diabetes) franchise sales declined 36% year over year to $487 million. The drug’s sales were hurt by lower ...